Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Solara Active Pharma Sciences
Small Cap•2,156 Employees•IPO 2018
Current Price
₹452.05
2.25 (0.5%)Updated
Today's Range
449
₹452.05
459
52 Week Range
52W Low₹440.20
52W High₹734.40
₹452.05
Downside2.69%
Upside62.46%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹2,334.8 Cr
Market Cap
Total market value of companyP/E Ratio
-
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
2.15
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹-4.81
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
-1.04%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
6.01%
ROCE
Return on Capital Employed. >15% is goodNet Margin
-1.52%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-68.33%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
-0.58%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-12.20%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
178.00%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.73
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹227.72
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
42.00%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Quarterly profit after tax surged 178.00% to 10.5 Cr.
- •Promoter holding increased to 42.01% from 30.49%, indicating confidence.
Weaknesses
5 points- •Extremely low profitability: ROE 0.54% and ROCE 6.01% indicate inefficient capital use.
- •High P/E ratio of 112.97 suggests the stock may be overvalued.
Opportunities
4 points- •Capitalize on increasing global healthcare expenditure within robust Pharmaceuticals sector.
- •Significant scope for operational improvements to enhance profitability metrics.
Threats
4 points- •Intense competition from larger, established pharmaceutical players with superior metrics.
- •High stock price volatility, evidenced by wide 52-week range (442.80-882.80).
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
Recent Insider Transactions
| Insider Name | Transaction Date | Filing Date | Total Shares | Change | Price | Action |
|---|---|---|---|---|---|---|
Pronomz Ventures LLP | 03 Feb 2025 | 05 Feb 2025 | 24.10 L | 78,000 | ₹516.68 | BUY |
Pronomz Ventures LLP | 11 Feb 2025 | 14 Feb 2025 | 24.44 L | 34,000 | ₹524.82 | BUY |
Pronomz Ventures LLP | 24 Feb 2025 | 28 Feb 2025 | 25.97 L | 1.52 L | ₹473.48 | BUY |
Pronomz Ventures LLP | 24 Feb 2025 | 04 Mar 2025 | 26.61 L | 2.16 L | ₹474.31 | BUY |
Pronomz Ventures LLP | 28 Feb 2025 | 06 Mar 2025 | 26.74 L | 13,600 | ₹461.5 | BUY |
Kausalya Santhanam | 11 Mar 2025 | 14 Mar 2025 | 1,876 | 1,000 | ₹500.06 | BUY |
Sandeep Shashikantha Rao | 04 Jun 2025 | 09 Jun 2025 | 1,000 | 1,000 | ₹473.99 | BUY |
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹477.70 | +₹25.65 | +5.67% |
| R3 | ₹467.70 | +₹15.65 | +3.46% |
| R2 | ₹463.35 | +₹11.30 | +2.50% |
| R1 | ₹457.70 | +₹5.65 | +1.25% |
| PIVOT | ₹453.35 | 1.30 | 0.29% |
| CURRENT | ₹452.05 | - | - |
| S1 | ₹427.70 | -₹24.35 | -5.39% |
| S2 | ₹437.70 | -₹14.35 | -3.17% |
| S3 | ₹443.35 | -₹8.70 | -1.92% |
| S4 | ₹447.70 | -₹4.35 | -0.96% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+6.2% vs avg
0.65L
(11 Mar 2026)Delivery %+6.3% vs avg
56.9%
(11 Mar 2026)Avg Volume (20D)20-day average
0.61L
(11 Feb - 11 Mar)Avg Delivery %Trend ↑
50.6%
(11 Feb - 11 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Bliss GVS Pharma Ltd
108.00 %
Highest Dividend Yield
RPG Life Sciences Ltd
1.22 %
Peer Comparison
| Company Name |
|---|
 Aarti Drugs Ltd |
 Amrutanjan Health Care Ltd |
 Bliss GVS Pharma Ltd |
 Gufic BioSciences Ltd |
 Hikal Ltd |
 Indoco Remedies Ltd |
 IOL Chemicals & Pharmaceuticals Ltd |
 Morepen Laboratories Ltd |
 Orchid Pharma Ltd |
 RPG Life Sciences Ltd |
 Senores Pharmaceuticals Ltd |
 SMS Pharmaceuticals Ltd |
 Sun Pharmaceutical Industries Ltd |
 Unichem Laboratories Ltd |
About
Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Limited is a global pharmaceutical company specializing in the manufacture, production, formulation, and distribution of active pharmaceutical ingredients (APIs). Their operations span a wide geographical area, including India, the Asia-Pacific region, Europe, North America, and South America, facilitating international trade and sales.
The company's API portfolio is extensive and covers a broad range of therapeutic areas. They produce APIs for various conditions, including amyotrophic lateral sclerosis, cardiovascular diseases, neurological disorders (like Parkinson's disease), infections (antibiotics, antifungals), and respiratory ailments (like asthma). Other therapeutic categories include anti-inflammatory, anti-cancer, anti-hypertensive, and anti-psychotic medications, amongst many others. The sheer breadth of their API offerings highlights their diverse capabilities and expertise within the pharmaceutical manufacturing sector.
Beyond API production, Solara Active Pharma Sciences also provides comprehensive contract research and manufacturing services (CRAMS). This service offering includes contract development and manufacturing of APIs, along with crucial support services such as analytical testing, impurity synthesis, and regulatory assistance. These added services enhance their value proposition to pharmaceutical clients seeking outsourced manufacturing and development solutions.
In essence, Solara Active Pharma Sciences Limited functions as a fully integrated pharmaceutical company. They not only manufacture and distribute a vast array of APIs for various therapeutic applications but also offer comprehensive CRAMS capabilities, enabling them to serve a diverse client base across the global pharmaceutical industry. Their international reach and broad portfolio position them as a significant player in the API market.
COMPANY FACTS - SOLARA
Registered Address
Second Floor, Admin Block, 27, Vandaloor Kelambakkam Road, Keelakottaiyur Village, Melakottaiyur (PO)
Chennai
TAMIL NADU
IN
Tel: 912227892924
Website:https://solara.co.in/
Investor Relations:http://www.solara.co.in/investor-relations/
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 2,156
IPO Date: 27/06/2018
MANAGEMENT - SOLARA
Mr. Sandeep Rao
Chief Executive Officer, Managing Director, Executive Director
Mr. Sarat Kumar
Chief Financial Officer
Mr. M. Mohan
Chief Operating Officer, Additional Executive Director
Mr. Rajeev Singh
Chief Human Resources Officer
Dr. Sudhir Nambiar
Chief Scientific Officer (Head R&D)
Ms. Pooja Kumar
Chief Compliance Officer, Company Secretary
Mr. Vishal Mathur
Chief Business Officer
Mr. V. Sundara Moorthy
Chief Quality Officer
Mr. Arun Pillai
Non-Executive Director
Mr. Kartheek Raju
Non-Executive Director
Mr. Ramakrishnan Rajagopal
Independent Director
Dr. Kausalya Santhanam
Independent Director
Investor Questions Answered
Solara Active Pharma Sciences Ltd (SOLARA) Stock FAQs
Get answers to the most common questions about Solara Active Pharma Sciences Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Solara Active Pharma Sciences Ltd (SOLARA) is ₹452.05. Today, the stock has gained by ₹2.25 (0.50%), trading in a range of ₹449 to ₹459. The stock opened at ₹450.1 with a trading volume of 64,903 shares.
Solara Active Pharma Sciences Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,334.8 crores, P/E ratio of 0.00, ROE of -1.04%, and ROCE of 6.01%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Solara Active Pharma Sciences Ltd (SOLARA) is ₹734.4, while the 52-week low is ₹440.2. Currently trading at ₹452.05, the stock is 4.0% away from its 52-week low and 38.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Solara Active Pharma Sciences Ltd stock at ₹452.05 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of N/A. Today's performance shows a gain of 0.50%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Solara Active Pharma Sciences Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹452.05, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Solara Active Pharma Sciences Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: N/A, ROE: -1.04%, ROCE: 6.01%, Dividend Yield: 0.00%, EPS: ₹-4.81, Book Value: ₹227.72, Debt-to-Equity: 0.73, and Current Ratio: N/A. The company's market cap stands at ₹2,334.8 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Solara Active Pharma Sciences Ltd stock opened at ₹450.1 and is currently trading at ₹452.05, showing a gain of ₹2.25 (0.50%). The intraday high is ₹459 and low is ₹449. The trading volume stands at 64,903 shares, indicating moderate market participation today.
Solara Active Pharma Sciences Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-4.81, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
Solara Active Pharma Sciences Ltd has a market capitalization of ₹2,334.8 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹452.05) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Solara Active Pharma Sciences Ltd has a book value of ₹227.72 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹452.05, which is 98.5% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Solara Active Pharma Sciences Ltd has a Return on Equity (ROE) of -1.04% and Return on Capital Employed (ROCE) of 6.01%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Solara Active Pharma Sciences Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Solara Active Pharma Sciences Ltd has a debt-to-equity ratio of 0.73, which measures the company's financial leverage by comparing total debt to shareholders' equity. This moderate ratio indicates balanced use of debt and equity. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Solara Active Pharma Sciences Ltd has an Earnings Per Share (EPS) of ₹-4.81, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹452.05 and P/E ratio of 0.00, investors are paying 0.00 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Solara Active Pharma Sciences Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Solara Active Pharma Sciences Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Solara Active Pharma Sciences Ltd stock, consider: 1) Fundamental Analysis - Review P/E (0.00), ROE (-1.04%), debt-to-equity (0.73), and growth rates. 2) Technical Analysis - Check 52-week range (₹440.20 - ₹734.40), moving averages, and chart patterns. 3) Valuation - Compare current price (₹452.05) with book value (₹227.72) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Solara Active Pharma Sciences Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹452.05 is 4421x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Solara Active Pharma Sciences Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹440.20 - ₹734.40). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.73 indicates leverage. 4) Liquidity Risk - Based on trading volume of 64,903 shares. 5) Valuation Risk - P/E of 0.00 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Solara Active Pharma Sciences Ltd operates in the industry with key metrics: P/E ratio of 0.00, ROE of -1.04%, market cap of ₹2,334.8 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.73), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Solara Active Pharma Sciences Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹452.05, with a 52-week range of ₹440.20 to ₹734.40. Based on fundamentals like P/E (0.00), ROE (-1.04%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Solara Active Pharma Sciences Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹452.05. 2) Fundamental Deterioration - Declining ROE (currently -1.04%), increasing debt (D/E: 0.73), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Solara Active Pharma Sciences Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu